Open Access
E3S Web Conf.
Volume 292, 2021
2021 2nd International Conference on New Energy Technology and Industrial Development (NETID 2021)
Article Number 03080
Number of page(s) 7
Section Environmental Sustainable Development and Industrial Transformation
Published online 09 September 2021
  1. “Coronavirus disease 2019 (COVID-19),” Mayo Clinic, 15-Apr-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  2. F. Li, “Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies,” Journal of Virology, vol. 89, no. 4, pp. 1954–1964, 2014. [CrossRef] [PubMed] [Google Scholar]
  3. S. Mallapaty, “China COVID vaccine reports mixed results — what does that mean for the pandemic?,” Nature, 2021, doi: 10.1038/d41586-021-00094-z. [Google Scholar]
  4. R. Staff, “China approves two more domestic COVID-19 vaccines for public use,” Reuters, 2021. [Google Scholar]
  5. S.-L. Wee, “China approves two more Covid-19 vaccines,” The New York Times, 2021. [Google Scholar]
  6. Z. Wu et al., “Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial,” The Lancet Infectious Diseases, 2021, doi: 10.1016/S1473-3099(20)30987-7. [Google Scholar]
  7. S. Xia et al., “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomized, double-blind, placebo-controlled, phase 1/2 trial,” The Lancet Infectious Diseases, vol. 21, no. 1, pp. 39–51, Jan. 2021, doi: 10.1016/S1473-3099(20)30831-8. [CrossRef] [PubMed] [Google Scholar]
  8. J. Huang, H. Huang, D. Wang, C. Wang, and Y. Wang, “Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID‐19,” Clinical and Translational Medicine, vol. 10, no. 6, Oct. 2020, doi: 10.1002/ctm2.184. [Google Scholar]
  9. “Understanding Viral Vector COVID-19 Vaccines,” Centers for Disease Control and Prevention. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  10. M. Voysey and A. J. Pollard, “ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 – Authors' reply,” The Lancet, vol. 396, no. 10261, pp. 1486–1487, 2020. [Google Scholar]
  11. M. D. Knoll and C. Wonodi, “Oxford–AstraZeneca COVID-19 vaccine efficacy,” The Lancet, vol. 397, no. 10269, pp. 72–74, 2021. [Google Scholar]
  12. “Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults -Full Text View,” Full Text View [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  13. S. Owermohle, “FDA confirms J&J vaccine is safe and effective,” POLITICO, 24-Feb-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  14. A. Koop, “Tracking COVID-19 Vaccines Around the World,” Visual Capitalist, 25-Jan-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  15. S. Ebbs, “Single-dose Johnson & Johnson vaccine effective against COVID-19 variants: Data,” ABC7 New York, 24-Feb-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  16. “Johnson & Johnson,” Content Lab U.S.[Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  17. 2021 Lianna Matt McLernon | News Writer | CIDRAP News | Mar 31, “AstraZeneca COVID vaccine 70% effective vs B117 variant,” CIDRAP, 31-Mar-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  18. A. C. Pinho, “AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets,” European Medicines Agency, 08-Apr-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  19. K. Kelland, G. Jones, and F. Guarascio, “Italy, Britain suggest age limits for AstraZeneca vaccine but still recommend it,” Reuters, 07-Apr-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  20. S. Owermohle, “FDA confirms J&J vaccine is safe and effective,” POLITICO, 24-Feb-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  21. “Covid: How does the Oxford-AstraZeneca vaccine work?,” BBC News, 15-Apr-2021. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  22. H. Branswell, “Comparing the Covid-19 vaccines developed by Pfizer, Moderna, and Johnson & Johnson,” STAT+, 2 February 2021. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  23. A. Martichoux, “AstraZeneca, Pfizer, Moderna, Johnson & Johnson: Breaking down the differences between coronavirus vaccines,” abc7news, 25 March 2021. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  24. I. A. B. J. A. A. S. M. D. C. K. S A Meo, “COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines,”, 2021. [Google Scholar]
  25. S. J. T.,. N. K. ,. J.A. ,.A.G. ,.S. L.,. J. L. P.,. G.P. M. ,. E. D. M. ,. C. Z. ,. R. B. ,. K. A. S. ,. S. R. ,. K. Fernando P Polack, “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine,” The new England journal of medicine, 2020. [PubMed] [Google Scholar]
  26. M. Wadman, “Public needs to prep for vaccine side effects,” Science, vol. 370, no. 6520, 2020. [Google Scholar]
  27. R. Staff, “Fact check: COVID-19 vaccines did have clinical trials,” Reuters, 3 February 2021. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  28. M. H.M. E.S. M.B. E.M.K.K. M.S.F.M. R.N. M. D. D. M. S.A. S. M. N. R. M. C. B. C. M. J. M. M. K. Lindsey R. Baden, “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine,” The New England journal of Medicine, 2021. [Google Scholar]
  29. S. Cao, “COVID-19 Vaccine Prices Revealed From Pfizer, Moderna, and AstraZeneca,” 23 November 2020. [Online]. Available: [Accessed 29 April 2021]. [Google Scholar]
  30. R. Staff, “Sinovac coronavirus vaccine offered by Chinese city for emergency use costs $60,” reuters, 16 October 2020. [Online]. Available: [Accessed 29 April 2021]. [Google Scholar]
  31. “Moderna Provides COVID-19 Vaccine Supply Update,” Moderna, 4 January 2021. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  32. “MANUFACTURING AND DISTRIBUTING THE COVID-19 VACCINE,” Pfizer, [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  33. R. Staff, “China Sinovac says it reached two billion doses annual capacity for COVID-19 vaccine,” Reuters, 2 April 2021. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  34. k. Makortoff, “AstraZeneca doubles capacity for potential Covid-19 vaccine to 2bn doses,” The guardian, 4 June 2020. [Online]. Available: [Accessed 12 April 2021]. [Google Scholar]
  35. Centers for Disease Control and Prevention, “Coronavirus Disease 2019 (COVID-19),” Centers for Disease Control and Prevention, Feb. 11, 2020. [Google Scholar]
  36. “The Sinovac COVID-19 vaccine: What you need to know,” [Google Scholar]
  37. W. N. Staff, “Three COVID Vaccines Compared,” WebMD. [Google Scholar]
  38. E. Mahase, “Covid-19: Where are we on vaccines and variants?,” BMJ (Clinical research ed.), vol. 372, p. n597, Mar. 2021, doi: 10.1136/bmj.n597. [Google Scholar]
  39. N. Franco, “Estudos mostram eficácia da CoronaVac contra três variantes do vírus,” Repórter da Agência Brasil, 2021. [Google Scholar]
  40. M. Terry, “Comparing COVID-19 Vaccines: Timelines, Types and Prices,” BioSpace, Feb. 08, 2021. [Google Scholar]
  41. C. N. N. P. Staff, “Inactivated vaccine safer way of doing vaccination, expert says,” cnn. [Online]. Available: ctivate-vaccine-coronavirus-safety.html. [Accessed: 27-Apr-2021]. [Google Scholar]
  42. S. Cao, “COVID-19 Vaccine Prices Revealed From Pfizer, Moderna, and AstraZeneca,” Observer, 23-Nov-2020. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  43. “COVID-19 Vaccine FAQs,” [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]
  44. Anne Trafton | MIT News Office, “Explained: Why RNA vaccines for Covid-19 raced to the front of the pack,” MIT News | Massachusetts Institute of Technology. [Online]. Available: [Accessed: 27-Apr-2021]. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.